LINDEN, N.J. , Aug.
20, 2024 /PRNewswire/ -- ACCU Reference Medical Laboratory, a leading provider of advanced diagnostic services, is proud to announce the implementation and availability of our new molecular PCR (Polymerase Chain Reaction) panels for the diagnosis of tick-borne diseases. This groundbreaking development promises to enhance the accuracy, speed, and comprehensiveness of diagnosing these diseases, ensuring better patient outcomes. Innovative Tick-Borne Disease Diagnostic Tick-borne diseases are a growing concern, nationwide, with cases on the rise, due to increasing tick populations and expanding geographic ranges.
These diseases, including Lyme Disease, Anaplasmosis, Babesiosis, Ehrlichiosis, and Rickettsia Species can present with non-specific symptoms that complicate diagnosis. Early and accurate detection is crucial for effective treatment and prevention of severe complications. The new molecular PCR panels introduced by ACCU Reference Medical Lab offer a highly sensitive and specific method for detecting various tick-borne pathogens.
This cutting-edge technology allows for the simultaneous identification of multiple pathogens in a single test, providing a comprehensive diagnostic solution. Key Benefits of the new PCR panels for diagnostic of tick-borne pathogens Enhanced Sensitivity and Specificity: The molecular PCR panels are designed to detect even low levels of pathogen DNA, ensuring accurate diagnosis even in early stages of infection. Rapid Turnaroun.